A Rational Design Strategy for Engineering CH4 Domain of IgE for Heterodimerization
Shikha Kumari1,2,3, Vanessa Siegmund4, Achim Doerner4
1Manipal Academy of Higher Education, Manipal, Karnataka, India.
Biotechnology and Bioengineering
|September 27, 2025
Summary
Researchers developed a computational method to create bispecific immunoglobulin E (IgE) antibodies for cancer immunotherapy. This novel approach enables the design of IgE bispecifics, enhancing potential treatments for solid tumors.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Bispecific antibodies are increasingly vital in cancer immunotherapy, with nine approvals between 2021-2023.
- Exploration of immunoglobulin E (IgE) isotypes shows potential for superior anti-tumor activity compared to immunoglobulin G (IgG) in certain cancers.
- Current limitations in developing bispecific IgE antibodies stem from a lack of effective heterodimerization technologies.
Purpose of the Study:
- To computationally design heterodimeric IgE antibodies.
- To adapt the established IgG knob-into-hole (KiH) strategy for IgE antibody engineering.
- To establish a proof of concept for developing novel therapeutic bispecific IgE antibodies.
Main Methods:
- Utilized a computational approach to design heterodimeric IgE antibodies.
- Applied the principles of the IgG knob-into-hole (KiH) strategy to IgE.
- Validated the functionality of the designed bispecific IgE variant.
Main Results:
- Successfully designed a novel variant of heterodimeric IgE antibodies.
- The engineered IgE bispecific retained essential target binding capabilities.
- Fc epsilon receptor engagement was confirmed for the novel IgE variant.
Conclusions:
- A computational strategy for designing heterodimeric IgE antibodies was successfully developed.
- This work provides a proof of concept for the future development of therapeutic bispecific IgE antibodies.
- The engineered bispecific IgE shows promise for enhancing cancer immunotherapy, particularly for solid tumors.
